474. Deputy Michael Lowry asked the Minister for Health the reasons pembrolizumab is reserved for the first-line treatment of certain cancers; the reason it is not approved for those currently receiving second-line cancer treatment therapy; if he will review the case of a person (details supplied); to initiate discussions with HSE officials to review the criteria for pembrolizumab as a second-line treatment option, emphasising the urgency and potential benefits of pembrolizumab for breast cancer treatment; and if he will make a statement on the matter. [27130/24]

Summary

474. Deputy Michael Lowry asked the Minister for Health the reasons pembrolizumab is reserved for the first-line treatment of certain cancers; the reason it is not approved for those currently receiving second-line cancer treatment therapy; if he will review the case of a person (details supplied); to initiate discussions with HSE officials to review the criteria for pembrolizumab as a second-line treatment option, emphasising the urgency and potential benefits of pembrolizumab for breast cancer treatment; and if he will make a statement on the matter. [27130/24]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Cancer Services

  xml · EN · 25 June 2024

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.